Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer.
Encephalitis
Immunotherapy
adverse effects
diabetes
durvalumab
small-cell lung cancer
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
08
2023
accepted:
29
09
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Durvalumab is an immune checkpoint Inhibitor (ICIs) that is used in the treatment of malignant tumors, such as lung cancer and melanoma. ICIs are associated with immune-related adverse events including autoimmune encephalitis, although both paraneoplastic phenomena and ICI treatment may lead to autoimmunity. We describe a 72-year old male patient with small-cell lung cancer, who during adjuvant treatment with Durvalumab developed GABA This case illustrates the importance of being aware of possible serious autoimmune adverse reactions, including neurological syndromes such as encephalitis, when treating patients with high risk of para-neoplasia with ICIs. In addition, the case shows the development of autoantibodies over time.
Sections du résumé
Background
Durvalumab is an immune checkpoint Inhibitor (ICIs) that is used in the treatment of malignant tumors, such as lung cancer and melanoma. ICIs are associated with immune-related adverse events including autoimmune encephalitis, although both paraneoplastic phenomena and ICI treatment may lead to autoimmunity.
Case presentation
We describe a 72-year old male patient with small-cell lung cancer, who during adjuvant treatment with Durvalumab developed GABA
Conclusion
This case illustrates the importance of being aware of possible serious autoimmune adverse reactions, including neurological syndromes such as encephalitis, when treating patients with high risk of para-neoplasia with ICIs. In addition, the case shows the development of autoantibodies over time.
Identifiants
pubmed: 37908347
doi: 10.3389/fimmu.2023.1278761
pmc: PMC10613972
doi:
Substances chimiques
durvalumab
28X28X9OKV
Antibodies, Monoclonal
0
Autoantibodies
0
gamma-Aminobutyric Acid
56-12-2
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1278761Informations de copyright
Copyright © 2023 Moss, Stavem, Aandahl, Gløersen, Grønberg, Neumann, Vedeler and Lundqvist.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lung Cancer. 2020 May;143:36-39
pubmed: 32200139
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Onco Targets Ther. 2021 Nov 03;14:5227-5236
pubmed: 34764654
J Neuroimmunol. 2018 Apr 15;317:84-89
pubmed: 29338930
Neurooncol Adv. 2020 May 05;2(1):vdaa057
pubmed: 32642709
Immunother Adv. 2022 May 27;2(1):ltac012
pubmed: 35814850
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):77-84
pubmed: 20800380
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Front Oncol. 2021 Jun 24;11:693279
pubmed: 34249743
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Neurol. 2020 Apr;267(4):1023-1025
pubmed: 31832829
Curr Oncol Rep. 2020 Mar 21;22(4):39
pubmed: 32200442
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Clin Apher. 2023 Apr;38(2):77-278
pubmed: 37017433
J Neurol. 2022 Mar;269(3):1701-1714
pubmed: 34708250
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Front Immunol. 2017 May 05;8:517
pubmed: 28529513
Am J Cancer Res. 2023 Aug 15;13(8):3275-3299
pubmed: 37693137
JAMA Neurol. 2021 Jul 1;78(7):864-873
pubmed: 33720308
J Immunother. 2021 Sep 1;44(7):243-247
pubmed: 33734140
Curr Oncol. 2022 Apr 24;29(5):3044-3060
pubmed: 35621637
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):656-64
pubmed: 23597420